Amyotrophic lateral sclerosis (ALS), first described by Jean-Martin Charcot in the 1870s, is
an age-related disorder that leads to degeneration of motor neurons. The disease begins …

Amyotrophic lateral sclerosis (ALS) is an age-related neurodegenerative disorder that is
believed to have complex genetic and environmental influences in the pathogenesis, but …

Objective To determine the diagnostic and prognostic performance of serum neurofilament
light chain (NFL) in amyotrophic lateral sclerosis (ALS). Methods This single-centre …

Objective Neuronal damage is the morphological substrate of persisting neurological
disability. Neurofilaments (Nf) are cytoskeletal proteins of neurons and their release into …

Objectives Biomarkers for the diagnosis of motoneuron diseases (MND) are urgently
needed to improve the diagnostic pathway, patient stratification and monitoring. The aim of …

Objective To examine neurofilament (Nf) concentrations according to symptom onset and
clinical diagnostic certainty categories of amyotrophic lateral sclerosis (ALS). Methods We …

Neurofilaments are elevated in the cerebrospinal fluid (CSF) and serum of amyotrophic
lateral sclerosis (ALS) patients. However, timing of this increase is unknown. To characterize …

The last 30 years have seen a major advance in the understanding of the clinical and
pathological heterogeneity of amyotrophic lateral sclerosis (ALS), and its overlap with …

Objectives Neurochemical markers of amyotrophic lateral sclerosis (ALS) that reflect
underlying disease mechanisms might help in diagnosis, staging and prediction of outcome …

Objective: To evaluate urinary neurotrophin receptor p75 extracellular domain (p75ECD)
levels as disease progression and prognostic biomarkers in amyotrophic lateral sclerosis …